Spur Therapeutics Announces Successful End-of-Phase 2 Meeting with FDA for FLT201, Its Gene Therapy Candidate for Gaucher Disease
FDA aligned on single-arm Phase 3 study to support potential accelerated and full approvalOn track to dose first patient in Phase 3 trial in ...
technologynetworks4d
How Cells Recycle Important Fat Molecules To Stay Healthy
New research has made a breakthrough in understanding how our cells manage to stay healthy by recycling important fat ...
TMCnet23d
Spur Therapeutics Announces Platform and Poster Presentations Highlighting New Clinical Data for FLT201 in Gaucher Disease at Upcoming WORLDSymposium
Results from GALILEO-1, a first in human clinical trial of FLT201 AAV-gene therapy in adult patients with Gaucher disease type 1 (Poster #318) Session: Poster Session III Date & Time: Thursday, ...
Enzyme Replacement Therapy Market Size, Growth & Forecast By 2033
The global enzyme replacement therapy market size was valued at USD 10.12 billion in 2024 and is projected to grow from USD 11.35 billion in 2025 to reach USD 21.29 billion by 2033, exhibiting a CAGR ...
Investing11d
Gene therapy FLT201 shows promise in Gaucher disease trial
Patients showed reductions in lyso-Gb1 levels, a biomarker of clinical response in Gaucher disease, ranging from 33% to 96%. Furthermore, the study observed maintenance of normal haemoglobin ...
Yahoo Finance12d
Spur Therapeutics Announces Successful End-of-Phase 2 Meeting with FDA for FLT201, Its Gene Therapy Candidate for Gaucher Disease
Lyso-Gb1 is one of the best predictors of clinical response in Gaucher disease, and FLT201 showed rapid and sustained reductions in lyso-Gb1 in its Phase 1/2 GALILEO-1 trial. Full approval would ...